Tag: AstraZeneca

Clinical Trials Healthcare & Pharmaceuticals News

AstraZeneca’s Breztri Triple-Therapy Hits Primary Goals in Landmark Phase III Asthma Trials

AstraZeneca

Groundbreaking data from the KALOS and LOGOS trials reveal that Breztri (BGF) triple-therapy significantly outperforms standard dual-combination inhalers for uncontrolled asthma. Published in The Lancet Respiratory Medicine, the study confirms a 76mL improvement in lung function and a meaningful reduction in severe exacerbations, signaling a potential shift in the global standard of care.

Business Healthcare & Pharmaceuticals News

AstraZeneca Delivers Robust 2025 Results as $58.7B Revenue as “Blockbuster” Portfolio Expands to 16 Medicines

AstraZeneca

AstraZeneca (AZN) capped off 2025 with a powerhouse performance, reaching $58.74 billion in total revenue and expanding its portfolio to 16 blockbuster drugs. With 100+ Phase III trials ongoing, CEO Pascal Soriot reaffirmed the company’s path to an $80 billion revenue target by 2030.

Business Healthcare & Pharmaceuticals News

AstraZeneca Posts Strong Q3 Results, Citing 11% Revenue Growth in 2025 Driven by Oncology and Pipeline Success

AstraZeneca

AstraZeneca has reported strong Q3 2025 results, driven by an 11% increase in Total Revenue for the first nine months of the year. The company’s success is fueled by a 16% growth in Oncology and significant advancements in its R&D pipeline, which has seen 16 positive Phase III trials year-to-date. AstraZeneca also reiterated its full-year guidance and highlighted strategic investments, including a new $4.5 billion manufacturing facility in the US.

Regulatory Approval News

AstraZeneca’s Tezspire Gains EU Approval for Nasal Polyps, Offering New Hope for Patients

AstraZeneca

The European Commission has officially approved AstraZeneca’s Tezspire (tezepelumab) for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP). This new add-on therapy offers hope for patients whose condition is uncontrolled by standard treatments, demonstrating efficacy in reducing polyp size, alleviating congestion, and decreasing the need for surgery.

Business News

AstraZeneca Strikes ‘Historic’ Drug Pricing Deal with US Government, Commits $50 Billion to US Manufacturing

AstraZeneca

AstraZeneca has announced a landmark agreement with the US government to significantly cut the cost of prescription medicines for millions of American patients via the Most-Favored-Nation (MFN) drug pricing model. The deal includes up to 98% discounts on key respiratory drugs for direct patient purchases and a $50 billion commitment to US manufacturing and R&D, securing a three-year exemption from threatened tariffs.

Clinical Trials News Oncology

AstraZeneca’s Tagrisso Combination Therapy Sets New Survival Benchmark in Advanced Lung Cancer

AstraZeneca

hase III trial called FLAURA2 has demonstrated that the combination of AstraZeneca’s drug, Tagrisso, with chemotherapy has led to a median overall survival of nearly four years for patients with a specific type of advanced lung cancer. This marks the longest survival benefit ever recorded in a global trial for this condition, solidifying Tagrisso as a standard-of-care treatment and providing a new benchmark for patient outcomes.

Clinical Trials Healthcare & Pharmaceuticals News

AstraZeneca’s Gefurulimab Shows Major Promise in Late-Stage Myasthenia Gravis Trial

AstraZeneca

AstraZeneca announced that its novel nanobody, gefurulimab, has successfully met its primary and all secondary endpoints in the PREVAIL Phase III trial for adults with generalized myasthenia gravis (gMG). The results showed that the once-weekly, self-administered treatment delivered statistically significant and clinically meaningful improvements in daily living activities for patients with this rare autoimmune disease.